Celastrol suppresses nitric oxide synthases and the angiogenesis pathway in colorectal cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Celastrol suppresses nitric oxide synthases and the angiogenesis pathway in colorectal cancer
Authors
Keywords
-
Journal
FREE RADICAL RESEARCH
Volume -, Issue -, Pages 1-11
Publisher
Informa UK Limited
Online
2019-02-18
DOI
10.1080/10715762.2019.1575512
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer
- (2018) Emerson Y. Chen et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Celastrol inhibits colorectal cancer cell proliferation and migration through suppression of MMP3 and MMP7 by the PI3K/AKT signaling pathway
- (2018) Tang Bufu et al. ANTI-CANCER DRUGS
- Tripterine alleviates LPS-induced inflammatory injury by up-regulation of miR-146a in HaCaT cells
- (2018) Ying Xiong et al. BIOMEDICINE & PHARMACOTHERAPY
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A Phase I Study of Irinotecan, Capecitabine (Xeloda), and Oxaliplatin in Patients With Advanced Colorectal Cancer
- (2018) Jean Maroun et al. Clinical Colorectal Cancer
- Capecitabine plus Oxaliplatin and Bevacizumab followed by Maintenance Treatment with Capecitabine and Bevacizumab for Patients > 75 Years with Metastatic Colorectal Cancer
- (2018) Roberto Petrioli et al. Clinical Colorectal Cancer
- A randomized phase III study of hepatic arterial infusion chemotherapy with 5-fluorouracil and subsequent systemic chemotherapy versus systemic chemotherapy alone for colorectal cancer patients with curatively resected liver metastases (Japanese Foundation for Multidisciplinary Treatment of Cancer 32)
- (2018) Toru Aoyama et al. Journal of Cancer Research and Therapeutics
- The influence of gut microbiota dysbiosis to the efficacy of 5-Fluorouracil treatment on colorectal cancer
- (2018) Lu Yuan et al. BIOMEDICINE & PHARMACOTHERAPY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The safety of ramucirumab for the treatment of colorectal cancer
- (2018) Alba Noguerido et al. Expert Opinion On Drug Safety
- Celastrol protects TGF-β1-induced endothelial-mesenchymal transition
- (2017) Fei Gong et al. Journal of Huazhong University of Science and Technology-Medical Sciences
- Angiogenesis inhibitors as therapeutic agents in cancer: Challenges and future directions
- (2016) Zhexuan Lin et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents
- (2016) Beverly L. Falcon et al. PHARMACOLOGY & THERAPEUTICS
- Celastrol induces proteasomal degradation of FANCD2 to sensitize lung cancer cells to DNA crosslinking agents
- (2015) Gui-Zhen Wang et al. CANCER SCIENCE
- Comparison ofTripterygium wilfordiiHook F with methotrexate in the treatment of rheumatoid arthritis
- (2014) Donald M Marcus ANNALS OF THE RHEUMATIC DISEASES
- Celastrol inhibits the HIF-1α pathway by inhibition of mTOR/p70S6K/eIF4E and ERK1/2 phosphorylation in human hepatoma cells
- (2014) JUAN MA et al. ONCOLOGY REPORTS
- Celastrol induces the apoptosis of breast cancer cells and inhibits their invasion via downregulation of MMP-9
- (2014) CHUNLIU MI et al. ONCOLOGY REPORTS
- Nitric oxide and cancer: a review
- (2013) Sheetal Korde Choudhari et al. World Journal of Surgical Oncology
- Modulation of inflammatory signaling and cytokine release from microglia by celastrol incorporated into dendrimer nanocarriers
- (2012) Sebastien Boridy et al. Nanomedicine
- Upregulating Noxa by ER Stress, Celastrol Exerts Synergistic Anti-Cancer Activity in Combination with ABT-737 in Human Hepatocellular Carcinoma Cells
- (2012) Hong Zhu et al. PLoS One
- AFM studied the effect of celastrol on β1 integrin-mediated HUVEC adhesion and migration
- (2012) Changhong Ke et al. SCANNING
- Up-regulation of death receptor 4 and 5 by celastrol enhances the anti-cancer activity of TRAIL/Apo-2L
- (2010) Hong Zhu et al. CANCER LETTERS
- Celastrol Suppresses Angiogenesis-Mediated Tumor Growth through Inhibition of AKT/Mammalian Target of Rapamycin Pathway
- (2010) X. Pang et al. CANCER RESEARCH
- Synergistic Anti-Cancer Activity by the Combination of TRAIL/APO-2L and Celastrol
- (2009) Hong Zhu et al. CANCER INVESTIGATION
- Celastrol, a novel HSP90 inhibitor, depletes Bcr–Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation
- (2009) Zhongzheng Lu et al. CANCER LETTERS
- Celastrol Potentiates Radiotherapy by Impairment of DNA Damage Processing in Human Prostate Cancer
- (2009) Yao Dai et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Celastrol Synergistically Enhances Temozolomide Cytotoxicity in Melanoma Cells
- (2009) M. Chen et al. MOLECULAR CANCER RESEARCH
- iNOS as a therapeutic target for treatment of human tumors
- (2008) Brian Fitzpatrick et al. NITRIC OXIDE-BIOLOGY AND CHEMISTRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search